Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances…
| Price | $0.50 |
|---|---|
| Market cap | $2.23M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | AMEX |
| 52-week range | 0.48-1.45 |
| Beta | 1.25 |
Explore OGEN's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.